Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Therapy, Gene

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,407 result(s) found for: Therapy, Gene. Displaying page 36 of 71.
    «« First « Previous 32  33  34  35  36  37  38  39  40  Next» Last»»
    EudraCT Number: 2013-000093-29 Sponsor Protocol Number: 9785-CL-1121 Start Date*: 2014-06-02
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer
    Medical condition: Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002713-34 Sponsor Protocol Number: ITCC-098 Start Date*: 2021-12-30
    Sponsor Name:Princess Maxima Center for Pediatric Oncology in The Netherlands
    Full Title: A Phase I/II study of Brigatinib in pediatric and young adult patients with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or other solid tumors
    Medical condition: relapsed/refractory ALK rearranged** or ALK mutated tumors, including relapsed/refractory ALK+ALCL and ALK+IMT.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) SE (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) NO (Prematurely Ended) BE (Trial now transitioned) FI (Trial now transitioned) PL (Trial now transitioned) AT (Ongoing) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023111-34 Sponsor Protocol Number: SG1/001/10 Start Date*: 2011-07-18
    Sponsor Name:Oxford BioMedica (UK) Ltd
    Full Title: A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected StarGen, Administered to Patients with Stargardt's Macular Degeneration.
    Medical condition: Stargardt Macular Dystrophy, also known as fundus flavimaculatus or Stargardt disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Not Authorised) IT (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-003715-38 Sponsor Protocol Number: D4190C00006 Start Date*: 2016-05-12
    Sponsor Name:MedImmune LLC
    Full Title: A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer
    Medical condition: Locally advanced or metastatic squamous or nonsquamous non- small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066490 Progression of non-small cell lung cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) DE (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-002377-21 Sponsor Protocol Number: M14-011 Start Date*: 2014-11-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant...
    Medical condition: Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) HU (Completed) GB (GB - no longer in EU/EEA) ES (Completed) IT (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-003222-76 Sponsor Protocol Number: ZX008-2103 Start Date*: 2022-08-19
    Sponsor Name:Zogenix International Limited
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, FIXED-DOSE, MULTICENTER STUDY TO EXAMINE THE EFFICACY AND SAFETY OF ZX008 IN SUBJECTS WITH CDKL5 DEFICIENCY DISORDER FOLLOWED BY AN OPEN-LABE...
    Medical condition: CDKL5 DEFICIENCY DISORDER
    Disease: Version SOC Term Classification Code Term Level
    22.1 10010331 - Congenital, familial and genetic disorders 10083005 CDKL5 deficiency disorder PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PT (Trial now transitioned) DE (Trial now transitioned) FR (Not Authorised) NL (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) IE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003926-24 Sponsor Protocol Number: EGF104900 Start Date*: 2006-01-30
    Sponsor Name:GlaxoSmithKline R&D Ltd
    Full Title: A randomized, multicentre, open-label Phase III study of lapatinib in combination with trastuzumab versus lapatinib monotherapy in subjects with metastatic breast cancer whose disease has progresse...
    Medical condition: Metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) FI (Completed) HU (Completed) AT (Completed) CZ (Completed) ES (Completed) IT (Completed) GR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003134-85 Sponsor Protocol Number: MK-3475-495 Start Date*: 2019-02-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)
    Medical condition: Treatment of advanced NSCLC
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (GB - no longer in EU/EEA) ES (Restarted) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005191-35 Sponsor Protocol Number: J2G-MC-JZJX Start Date*: 2021-11-22
    Sponsor Name:Eli Lilly and Company
    Full Title: LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positi...
    Medical condition: Adjuvant Selpercatinib following definitive locoregional treatment in male or female patients with stage IB-IIIA RET fusion positive NSCLC
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) AT (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) NO (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002918-12 Sponsor Protocol Number: CC-10004-PPSO-003 Start Date*: 2019-03-25
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Apremilast (CC-10004) in Pediatric Subjects from 6 through 17 Years of Age with Mode...
    Medical condition: Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) CZ (Completed) HU (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000178-20 Sponsor Protocol Number: MCT8-2014-1 Start Date*: 2015-08-12
    Sponsor Name:Erasmus Medical Centre
    Full Title: Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial.
    Medical condition: This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic ...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: BE (Completed) CZ (Completed) DE (Completed) IT (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001599-40 Sponsor Protocol Number: 23032013 Start Date*: 2014-01-03
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus as prototypic au...
    Medical condition: Patients with systemic lupus erythematosus (SLE) and increased disease activity refractory to standard therapies.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    18.0 10022891 - Investigations 10067657 Systemic lupus erythematosus disease activity index increased PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002598-22 Sponsor Protocol Number: MK-3475-782 Start Date*: 2018-10-19
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II Trial to Investigate Genetic Markers of Response to Pembrolizumab (MK-3475, SCH 900475) Combined with Chemotherapy as a First-line Treatment for Non-Small Cell Lung Cancer (KEYNOTE-782)
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-002633-38 Sponsor Protocol Number: 08781 Start Date*: 2018-11-19
    Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: An open label phase I/IIa trial repurposing carbamazepine (CBZ) for the treatment of skeletal dysplasia in children.
    Medical condition: Metaphyseal chondrodysplasia type Schmid (MCDS)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004195-19 Sponsor Protocol Number: CREPATS10 Start Date*: 2020-07-07
    Sponsor Name:Centre de Recherche et d’Etudes sur la Pathologie Tropicale et le Sida (CREPATS)
    Full Title: A randomized comparative phase II trial evaluating the capacity of the dual combination doravirine/raltegravir to maintain virological success in HIV-1 infected patients with an HIV-RNA plasma vire...
    Medical condition: HIV disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10020160 HIV disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005117-72 Sponsor Protocol Number: AG120-C-005 Start Date*: 2017-04-24
    Sponsor Name:Agios Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation
    Medical condition: Nonresectable or Metastatic Cholangiocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10008594 Cholangiocarcinoma non-resectable LLT
    20.0 100000004864 10077846 Cholangiocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002063-17 Sponsor Protocol Number: ETOP12-17 Start Date*: 2018-02-19
    Sponsor Name:ETOP (European Thoracic Oncology Platform)
    Full Title: A single arm phase II trial evaluating the activity of alectinib for the treatment of pretreated RET-rearranged advanced NSCLC
    Medical condition: Advanced stage RET-rearranged NSCLC
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed) NL (Completed) SI (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020911-35 Sponsor Protocol Number: GS-US-196-0123 Start Date*: 2011-01-17
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With GS-9190, GS-9256, Ribavirin (Copegus®) and Peginterferon Alfa 2a (Pegasys®)...
    Medical condition: Chronic Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) DE (Completed) GB (Prematurely Ended) BE (Prematurely Ended) AT (Completed) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001773-26 Sponsor Protocol Number: 100554 Start Date*: 2005-05-03
    Sponsor Name:Bayer HealthCare AG, D-51368 Leverkusen Germany
    Full Title: A Phase III randomized, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinoma
    Medical condition: Advanced hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    7.1 10049010 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) BE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-000482-36 Sponsor Protocol Number: CL02-ORY-1001AML Start Date*: 2018-09-07
    Sponsor Name:Oryzon Genomics S. A.
    Full Title: A pilot study to assess the safety, tolerability, dose finding and efficacy of ORY-1001 in combination with azacitidine in older patients with AML in first line therapy.
    Medical condition: Patients with acute mieloyd leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10024349 Leukemia myeloid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 32  33  34  35  36  37  38  39  40  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 08 07:46:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA